drugset
drugset / Trial / NCT02405065

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573

NCT02405065 ↗

Phase 1 Completed 72 enrolled Hanmi Pharmaceutical Company Limited
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.

Timeline

Start
2015-01-12
Primary completion
2017-01-18
Completion
2018-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject HM95573 Unknown — Oral

Indications

neoplasm